ClinicalTrials.gg
CompletedNCT03991936Updated Mar 27, 2024Results posted

Benefit of Placebo and Different Concentrations of Triamcinolone Acetonide in Nail Psoriasis

A Phase 4 interventional study of Placebos and Triamcinolone Acetonide 2.5 mg/mL in Nail Psoriasis and Nail Diseases, sponsored by Weill Medical College of Cornell University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-27.

Sponsored by Weill Medical College of Cornell University · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
11
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This purpose of this study is to determine the lowest effective concentration of intralesional triamcinolone acetonide in the treatment of nail psoriasis.

02

Conditions studied

  • Nail Psoriasis
  • Nail Diseases

Keywords

  • Nail Psoriasis
  • Nail Diseases
  • Triamcinolone acetonide
  • Triamcinolone
03

In context

Lead sponsor

Weill Medical College of Cornell University is the lead sponsor of 892 studies on the registry; 165 are open to participants now.

Of its 123 completed or terminated interventional studies of FDA-regulated products, 94 (76%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age
  • Diagnosed with nail psoriasis in at least 2 fingernails
  • Willing to give written and able to adhere to procedures and visit schedules
  • Must consent to having the fingernails photographed during the study period

Exclusion criteria

Exclusion Criteria:

  • Subject with any condition or situation, other than the condition being studied that, in the opinion of the investigator, would interfere with study evaluations or optimal participation in the study. This is including, but not limited to: immunodeficiency, onychomycosis, any other nail condition other than psoriasis, allergy to triamcinolone acetonide, local anesthetic, normal saline, or any other material used for procedures
  • Subject who has received radiation therapy, chemotherapy, and/or drugs within 6 months of study, and/or oral for >1 month within the 6 months of study (exception: inhaled steroids)
  • Subject known to have received treatment with drugs or devices within 30 days prior to enrollment into this study
  • Subject who is unwilling to abstain from any cosmetic nail treatments outside those provided by the study clinic, beyond basic nail trimming (i.e. no spa nail treatments, no nail polish use, no other topical prescription nail medication)
  • Subject who is unwilling to abstain from any medical nail treatments on their nails other than the study intervention (i.e. topical steroids, anti-fungal creams) for the duration of the study intervention and for duration of the (if applicable)
  • Subject who is part of the staff personnel directly involved with this study or a family member of the investigational study staff
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
11 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Participants receive an intralesional injection of 0.1-0.2 mL of normal saline in one psoriatic fingernail once per 6 weeks until 24 weeks.

    Drug: Placebos

  • Experimental
    Triamcinolone Acetonide 2.5 mg/mL

    Participants receive an intralesional injection of 0.1-0.2 mL of 2.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.

    Drug: Triamcinolone Acetonide 2.5 mg/mL

  • Experimental
    Triamcinolone Acetonide 5.0 mg/mL

    Participants receive an intralesional injection of 0.1-0.2 mL of 5.0 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.

    Drug: Triamcinolone Acetonide 5.0 mg/mL

  • Experimental
    Triamcinolone Acetonide 7.5 mg/mL

    Participants receive an intralesional injection of 0.1-0.2 mL of 7.5 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.

    Drug: Triamcinolone Acetonide 7.5 mg/mL

  • Experimental
    Triamcinolone Acetonide 10 mg/mL

    Participants receive an intralesional injection of 0.1-0.2 mL of 10 mg/mL intralesional triamcinolone acetonide in one psoriatic fingernail once per 6 weeks until 24 weeks.

    Drug: Triamcinolone Acetonide 10 mg/mL

Interventions

  • DrugPlacebos

    Normal saline intralesional injection

    Also known as: Saline solution for injection

  • DrugTriamcinolone Acetonide 2.5 mg/mL

    Drug page: Triamcinolone Acetonide

    2.5 mg/mL intralesional injection

    Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension

  • DrugTriamcinolone Acetonide 5.0 mg/mL

    Drug page: Triamcinolone Acetonide

    5.0 mg/mL intralesional injection

    Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension

  • DrugTriamcinolone Acetonide 7.5 mg/mL

    Drug page: Triamcinolone Acetonide

    7.5 mg/mL intralesional injection

    Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension

  • DrugTriamcinolone Acetonide 10 mg/mL

    Drug page: Triamcinolone Acetonide

    10 mg/mL intralesional injection

    Also known as: Triamcinolone Injection, Kenalog 10 MG/ML Injectable Suspension

06

What researchers measure

Primary outcomes

  1. Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis

    The most effective concentration of intralesional triamcinolone acetonide will be determined between 0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 7.5 mg/mL, and 10.0 mg/mL.

    Time frame: 24 weeks (end of study)

Secondary outcomes

  1. Change From Baseline in Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)

    The Nail Psoriasis Severity Index (NAPSI) is used to evaluate nail psoriasis. Scores range from 0 to 8 with 0 indicating no nail psoriasis and higher scores indicating worsening nail psoriasis.

    Time frame: Baseline, 24 weeks (end of study)

  2. Change From Baseline in Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)

    The NPQ10 comprises 10 questions gauging the impact of nail psoriasis on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, reflecting the proportion of questions answered by the patient. The obtained score correlates proportionally with the level of functional difficulty experienced, with 0% indicating no impairment and 100% indicating the worst possible impairment.

    Time frame: Baseline, 24 weeks (end of study)

  3. Number of Participants With at Least One Adverse Event

    Adverse events will only include those that are determined to be related to the study drug.

    Time frame: 24 weeks (end of study)

07

Results

Posted Mar 27, 2024

Participant flow

Participants were recruited from one location in the United States

Participant flow — Overall Study
MilestonePlaceboTriamcinolone Acetonide 2.5 mg/mLTriamcinolone Acetonide 5.0 mg/mLTriamcinolone Acetonide 7.5 mg/mLTriamcinolone Acetonide 10 mg/mL
Started1111111111
Completed1010101010
Not completed11111
Withdrew: Lost to follow-up11111

Outcome measures

PrimaryLowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis

The most effective concentration of intralesional triamcinolone acetonide will be determined between 0 mg/mL, 2.5 mg/mL, 5.0 mg/mL, 7.5 mg/mL, and 10.0 mg/mL.

Time frame:
24 weeks (end of study)
Reported as:
Number · mg/mL
Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis
mg/mLAll Groups
Lowest Effective Concentration of Intralesional Triamcinolone Acetonide for Nail Psoriasis2.5
SecondaryChange From Baseline in Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)

The Nail Psoriasis Severity Index (NAPSI) is used to evaluate nail psoriasis. Scores range from 0 to 8 with 0 indicating no nail psoriasis and higher scores indicating worsening nail psoriasis.

Time frame:
Baseline, 24 weeks (end of study)
Reported as:
Mean · score on a scale
Change From Baseline in Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)
score on a scalePlaceboTriamcinolone Acetonide 2.5 mg/mLTriamcinolone Acetonide 5.0 mg/mLTriamcinolone Acetonide 7.5 mg/mLTriamcinolone Acetonide 10 mg/mL
Change From Baseline in Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)-0.96 (-1.81 to -0.11)-3.96 (-4.64 to -3.27)-2.96 (-3.62 to -2.31)-3.53 (-4.2 to -2.85)-3.93 (-4.62 to -3.24)
Statistical analysis
  • Placebo vs Triamcinolone Acetonide 2.5 mg/mL vs Triamcinolone Acetonide 5.0 mg/mL vs Triamcinolone Acetonide 7.5 mg/mL vs Triamcinolone Acetonide 10 mg/mL · t-test, 2 sided · p = <0.001 (The threshold for statistical analysis was p = 0.05) · Mean difference (net): -2.635
SecondaryChange From Baseline in Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)

The NPQ10 comprises 10 questions gauging the impact of nail psoriasis on daily activities. Each response is scored from 0 to 2, resulting in a total score between 0 and 20, where higher values indicate a more significant impact. The final scores are converted to percentages, reflecting the proportion of questions answered by the patient. The obtained score correlates proportionally with the level of functional difficulty experienced, with 0% indicating no impairment and 100% indicating the worst possible impairment.

Time frame:
Baseline, 24 weeks (end of study)
Reported as:
Mean · percentage of NPQ10 score
Change From Baseline in Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)
percentage of NPQ10 scoreAll Groups
Change From Baseline in Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality of Life Scale (NPQ10)4.5 (0 to 15)
SecondaryNumber of Participants With at Least One Adverse Event

Adverse events will only include those that are determined to be related to the study drug.

Time frame:
24 weeks (end of study)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Adverse Event
ParticipantsTriamcinolone Acetonide 2.5 mg/mLTriamcinolone Acetonide 5.0 mg/mLTriamcinolone Acetonide 7.5 mg/mLTriamcinolone Acetonide 10 mg/mLPlacebo
Number of Participants With at Least One Adverse Event34780

Adverse events

Collected over 24 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/10 (0%)0/10 (0%)0/10 (0%)
Triamcinolone Acetonide 2.5 mg/mL0/10 (0%)0/10 (0%)4/10 (40%)
Triamcinolone Acetonide 5.0 mg/mL0/10 (0%)0/10 (0%)6/10 (60%)
Triamcinolone Acetonide 7.5 mg/mL0/10 (0%)0/10 (0%)10/10 (100%)
Triamcinolone Acetonide 10 mg/mL0/10 (0%)0/10 (0%)8/10 (80%)
Most frequent other events
Most frequent other events
EventPlaceboTriamcinolone Acetonide 2.5 mg/mLTriamcinolone Acetonide 5.0 mg/mLTriamcinolone Acetonide 7.5 mg/mLTriamcinolone Acetonide 10 mg/mL
Cuticle retractionSkin and subcutaneous tissue disorders0/101/103/104/104/10
OnychomadesisSkin and subcutaneous tissue disorders0/102/100/102/101/10
ErythronychiaSkin and subcutaneous tissue disorders0/101/101/101/102/10
Subungual hematomaSkin and subcutaneous tissue disorders0/101/101/101/100/10
Longitudinal grooveSkin and subcutaneous tissue disorders0/100/100/101/100/10
Beau's line(s)Skin and subcutaneous tissue disorders0/101/101/101/101/10
Nail plate splitSkin and subcutaneous tissue disorders0/100/100/100/101/10
Nail plate concavitySkin and subcutaneous tissue disorders0/100/100/100/101/10

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Participants
Mean51 ± 13
Sex: Female, Male
Sex: Female, Male(Participants)All Participants
Female7
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino1
Not Hispanic or Latino10
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)All Participants
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White9
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)All Participants
United States11
Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality
Nail Psoriasis Qualify of Life, as Measured by Development and Validation of Nail Psoriasis Quality(percentage of NPQ10 score)All Participants
Mean7 (0 to 30)
Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)
Nail Psoriasis, as Measured by Nail Psoriasis Severity Index (NAPSI)(score on a scale)All Participants
Triamcinolone acetonide 2.5 mg/mL5.3 (3 to 8)
Triamcinolone acetonide 5.0 mg/mL4.76 (3 to 7)
Triamcinolone acetonide 7.5 mg/mL4.75 (3 to 7)
Triamcinolone acetonide 10 mg/mL5.0 (3 to 8)
Placebo4.7 (3 to 6)
Total4.9 (3 to 8)
08

Study locations

1 site
  • Weill Medical College of Cornell University
    New York, New York 10021, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Mar 2023, 36 months.

Results were first posted in Mar 2024, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 18, 2019
First posted
Jun 19, 2019
StartActual
Mar 11, 2020
Primary completionActual
Mar 29, 2023
CompletionActual
Mar 29, 2023
Results first posted
Mar 27, 2024
Last update
Mar 27, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 27, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03991936
Responsible party
Sponsor
First posted
Jun 19, 2019
Start date
Mar 11, 2020
Primary completion
Mar 29, 2023
Completion
Mar 29, 2023
Results posted
Mar 27, 2024
Last update
Mar 27, 2024

Study contacts

Shari Lipner, MD, PhD
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Triamcinolone Acetonide

Start the discussion